Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level
Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level is a paper indexed in PICO Portal from OpenAlex.
How many citations does Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level have?
Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level has 129 citations in the OpenAlex counts PICO Portal stores.
When was Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level published?
Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level has 2003 year in the PICO Portal index.
What is the open-access status of Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level?
Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level has bronze oa status in the PICO Portal index.
What is the DOI of Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level?
The DOI for Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level is on the source record.
What is the PMID of Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level?
The PMID for Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level is on the source record.
What is the OpenAlex record for Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level?
The OpenAlex for Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level is on the source record.